Okabe Hirohisa, Hashimoto Daisuke, Chikamoto Akira, Yoshida Morikatsu, Taki Katsunobu, Arima Kota, Imai Katsunori, Tamura Yoshitaka, Ikeda Osamu, Ishiko Takatoshi, Uchiyama Hideaki, Ikegami Toru, Harimoto Norifumi, Itoh Shinji, Yamashita Yo-Ichi, Yoshizumi Tomoharu, Beppu Toru, Yamashita Yasuyuki, Baba Hideo, Maehara Yoshihiko
Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ann Surg Oncol. 2017 May;24(5):1399-1405. doi: 10.1245/s10434-016-5630-4. Epub 2016 Nov 28.
Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential.
Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed.
Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 %), lymph node metastasis (36 vs. 3 %), pathologic capsular invasion (68 vs. 8 %), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 %), and histologic grade 2/3 (41 vs. 0 %). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041).
Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.
胰腺神经内分泌肿瘤(PNET)恶性潜能的预后指标有限。我们评估了对比增强计算机断层扫描上的肿瘤形态和强化模式,作为恶性潜能的预测指标。
2001年至2014年接受根治性手术的60例PNET患者纳入我们的回顾性研究。评估术前增强CT,并为形状规则且强化的肿瘤(第1组)和形状不规则和/或强化的肿瘤(第2组)定义标准。评估肿瘤形态和强化模式与预后的关系。
观察者间一致性较高(kappa = 0.74)。第2组(n = 24)与同时性肝转移(23% 对0%)、淋巴结转移(36% 对3%)、病理包膜侵犯(68% 对8%)、肿瘤较大尺寸(30对12mm)、肿瘤、淋巴结、转移分类系统(TNM)III/IV期疾病(46% 对3%)以及组织学2/3级(41% 对0%)显著相关。多因素分析显示,肿瘤2/3级和第2组标准与肿瘤复发相关(风险比分别为6.5和13.6,P = 0.0071和0.039),且只有第2组标准与总体生存不良独立相关(风险比5.56e + 9,P = 0.0041)。
术前计算机断层扫描显示肿瘤形状/强化不规则是PNET根治性手术后的不良预后因素。